Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

UTHR Stock Surges: Time to Dive In?

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 9/2/2025, 2:32 pm ET | 5 min
UTHR Stock Surges: Time to Dive In? Thumbnail

In this article Last trade Sep, 02 2:40 PM

  • UTHR+34.15%
    UTHR - NYSEUnited Therapeutics Corporation
    $408.83+104.07 (+34.15%)
    Volume:  2.28M
    Float:  40.57M
    $402.28Day Low/High$465.00

United Therapeutics Corporation’s stocks have been trading up by 35.18% due to FDA designations and promising results.

  • UBS maintains a Buy rating on United Therapeutics, setting a new price target at $415, up from the previous $385.

Candlestick Chart

Live Update At 14:32:01 EST: On Tuesday, September 02, 2025 United Therapeutics Corporation stock [NASDAQ: UTHR] is trending up by 35.18%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

United Therapeutics Financial Highlights

As a trader, navigating the volatile world of stock markets requires resilience and adaptability. Each day presents new challenges, and the path to success is seldom straightforward. As millionaire penny stock trader and teacher Tim Sykes, says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” This mindset helps traders learn from their setbacks and refine their skills over time, turning potential losses into opportunities for growth and improvement. The key is to remain patient and persistent, allowing these experiences to shape and enhance trading tactics.

United Therapeutics recently released their earnings report, and the numbers present an intriguing picture. With a current price-to-earnings ratio of 11.88, the company exceeds its competitors, indicating it offers value relative to its earnings. Gross margins stand an impressive 89%, hinting at significant profitability through their various product lines. A liquidity snapshot shows a strong current ratio of 7.3, portraying their solid capability to meet short-term liabilities.

In recent financial statements, United Therapeutics reported total revenue close to $2.88 billion, showing remarkable growth. In a chat with an experienced investor, he mused how, years ago, they hoped this company would steadily climb, and now, with revenue per share at $63.62, it seems those hopes were well-founded. Their operating cash flow of $191.7 million showcases a robust and healthy stance. Meanwhile, research and development expenses of $134 million reflect their continued investment in innovation, vital in the competitive pharma sector.

Key Developments and Their Impact

The uptick in stock price can be attributed to several pivotal developments. Primarily, optimism fueled by UBS’s revised price target amplifies investor confidence. As Verma gives a thumbs-up to the stock’s future potential, market participants rally behind the bullish sentiment. Additionally, the firm’s study on their Tyvaso product appears to be a cornerstone, encouraging a slew of new investor interests.

The strategic insights provided by Verma, which aligns perfectly with other investors’ hopes, are a beacon for mid-term holdings. Historically, price target hikes following successful clinical trial results boost investor morale, guiding the stock upward. This demonstrates the power of extensive research and establishing a trusted picture of the company’s future path.

More Breaking News

Reflections on Current Market Trends

Let’s dive into what the charts are saying. Beginning at around $420, the price faced a roller coaster during the day, touching peaks of $436 before consolidating to a close of $412. Intraday trades revealed patterns of breakouts and pullbacks, painting a broader picture of interest buoyed by recent news. Remember those giddy moments in school when acing a big test? The market’s reaction feels akin to that joyous relief.

With United Therapeutics fabricating waves in the market, the current rally might not be a mere flash in the pan. Analysts allude to consistent growth rooted in a solid foundation, underscoring ongoing developments. Traders might ponder whether this surge offers a perfect entry point, possibly leading to lucrative returns down the line. As millionaire penny stock trader and teacher Tim Sykes says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.” This prudent approach may guide our path amidst the excitement. The hot topic remains: will the momentum persist?

As the dust settles, stake levels become prime areas to watch. With calculated steps and informed decisions, United Therapeutics might be on the verge of unlocking greater opportunities, forging new paths not merely for its current stakeholders but for future traders ready to ride the potential wave.

Ultimately, as the market continues to analyze these ongoing events and predictions, stakeholders will want to stay tuned as United Therapeutics maintains its strides.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

In this article (YTD Performance)

  • UTHR-13.63%
    UTHR - NYSEUnited Therapeutics Corporation
    $408.83+104.07 (+34.15%)
    Volume:  2.28M
    Float:  40.57M
    $402.28Day Low/High$465.00

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Join Thousands Profiting From Smart Trades!
TRADE LIKE TIM

We use cookies to provide you with the best online experience. If you continue browsing, we consider that you accept our Cookie Policy , and also agree to the terms of our Privacy Policy and Terms of Use.

notification icon
Subscribe to receive notifications